<DOC>
	<DOCNO>NCT01235416</DOCNO>
	<brief_summary>This study open-label , dose-finding study determine target maximum-tolerated dose characterize safety pharmacokinetic profile AMG 706 administer combination erlotinib without gemcitabine subject solid tumor .</brief_summary>
	<brief_title>A Phase 1b , Open-label , Dose-finding Study AMG 706 Combination With Gemcitabine Erlotinib Treat Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>histologically cytologically document solid tumor candidate gemcitabine erlotinib treatment ( cohort gemcitabine ) , opinion investigator candidate erlotinib treatment ( cohort without gemcitabine ) , opinion investigator Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 ( see Appendix E ) systolic blood pressure ≤ 145 mm Hg diastolic blood pressure ≤ 85 mm Hg ( hypertension therapy allow ) least 18 year age write informed consent obtain studyspecific procedure perform , appropriate approve write informed consent must obtain ( Section 12.1 ) . nonsmallcell lung cancer squamouscell histology large central tumor lesion ( ie , ≥ 3 centimeter locate adjacent within hilum mediastinum ) direct bowel wall invasion except primary tumor bowel evidence active bleeding bleed diathesis total gastrectomy hematologic malignancy untreated symptomatic brain metastasis history evidence interstitial lung disease past current history second neoplasm , except curatively treat nonmelanoma skin cancer , carcinoma situ cervix primary solid cancer know active disease present curative treatment administer last 3 year document myocardial infarction within 1 year study day 1 arterial thrombosis deep vein thrombosis within 1 year study day 1 unstable uncontrolled disease/condition relate impacting cardiac function ( eg , unstable angina , congestive heart failure , New York Heart Association ( NYHA ) &gt; class II [ Appendix F ] ) major surgical procedure within 30 day study day 1 know positive test human immunodeficiency virus ( HIV ) absolute neutrophil count ( ANC ) &lt; 1.5 x 109 /L platelet count &lt; 100 x 109 /L &gt; 850 x 109 /L hemoglobin &lt; 9 g/dL serum creatinine &gt; 2.0 mg/dL calculate clearance &lt; 40 mL/minute albuminadjusted serum calcium &lt; 2.0 mmol/L ( 8.0 mg/dL ) urine protein quantitative value ≥ 30 mg/dL urinalysis ≥ 1+ dipstick , unless 24hour urine protein &lt; 500 mg aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) AST ALT &gt; 5.0 x ULN subject document liver metastasis primary hepatic neoplasm total bilirubin &gt; 2 x ULN ( &gt; 3 x ULN subject Gilbert syndrome . Subjects UGT1A1 promoter polymorphism , i.e . Gilbert syndrome , must confirm genotyping Invader® UGT1A1 Molecular Assay ) prothrombin time &gt; 2.0 international normalize ratio partial thromboplastin time &gt; 1.5 X ULN currently previously treat bevacizumab small molecular inhibitor VEGF include limited SU11248 ( sunitinib malate ) , PTK787 ( vatalanib ) , AZD 2171 , AEE788 , BAY 43 9006 ( sorafenib tosylate ) AMG 706 , unless approve Amgen previously treat erlotinib previously treat gemcitabine ( cohort gemcitabine ) unless approve Amgen currently treat interferon systemic chemotherapy within 21 day study day 1 radiation therapy within 14 day study day 1 concurrent prior treatment rifampin , rifabutin , rifapentin , phenytoin , carbamazepine , phenobarbital within 14 day study day 1 treatment strong CYP 3A inhibitor inducer ( limited ketoconazole , itraconazole , clarithromycin , erythromycin nefazodone ) immune modulators ( limited cyclosporine tacrolimus ) 7 day study day 1 treatment herbal medication contain St John 's Wort within 7 day study day 1 treatment systemic infection within 14 day study day 1 treat &gt; 1 mg/day warfarin within 7 day study day 1 condition investigator 's opinion make subject unsuitable study participation yet complete least 30 day since end investigational device/drug trial ( ) , subject receive investigational treatment pregnant ( ie , positive betahuman chorionic gonadotropin test ) breast feed use adequate contraceptive precaution unable swallow oral medication previously enrol study available followup assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>